|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Nutritional Status,Sarcopenia and the Importance of Prehabilitation of Gastrointestinal Tumor Patients:a Surgical Point of View显示文摘Background Surgery may be the field of healthcare where malnutrition and sarcopenia have their greatest impact on patient morbidity and mortality.However,there are limited data on the nutritional status of surgical patients and the effects of prehabilitation on the outcomes of surgery.Methods A prospective analysis was conducted on all patients surgically-treated for malignant gastrointestinal tumors at St.John Hospital during a two-year period.The patient’s gender,age,body weight,height,BMI and weight loss were registered,then a risk score was determined by the MUST survey.Measurement of the triceps and thigh skin-fold thickness and the circumference of the upper arm and thigh were done to calculate muscle area and muscle index,respectively.The body composition was assessed using an OMRON-BF511 device.Muscle function was evaluated based on hand clamping force measurement and activity tests.Patients who were diagnosed as being at-risk received preoperative prehabilitation,which included physiotherapy and nutritional therapy.Results A total of 231 patients(133 males/98 females)were analyzed.They had a mean age of 68.9 years(18~98).Seventy-four patients(32%)lost weight,with an average loss of 7 kilograms(3~15 kg).Anthropometric data showed an average upper-arm circumference of 27.4 cm(14.3~38.1)and thigh circumference of 44.7 cm(19.3~60.1),so the median muscle index was 1.29.The mean BMI was 26,which is above normal,and the elevated BMI was consistent documented in each patient subgroup stratified by age and tumor type.A body composition analysis was performed for 75 patients(44 male/31 female),who had a median age of 68(37~88 y).The average BMI of these patients was 25.7 y and their average MUST score was 1.12.The total body fat percentage(of the total body mass)was 29.5%,total muscle was 30.1%and visceral fat was 10%.Thirty patients(40%)had sarcopenia,with a mean BMI of 28.7,fat comprising 34.2%of the body mass,visceral-fat 11%,and muscle 27.1%,and their median MUST score was 1.23.Patients who received preoperative training(physiotherapy)showed improvements in physical function ranging from 12%~33%.Conclusion Gastrointestinal tumor patients have a higher than normal BMI regardless of age or tumor type.Patients with sarcopenia show measurable improvement after two weeks of prehabilitation. | Péter Lukovich Ákos Nagy Bianka Barok Borbála Csiba Ram Rokka Balázs Pőcze | 2020 | Journal of Nutritional Oncology2020，5，3： | 2 |
| 2 | Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer显示文摘 | Mark Barok Minna Tanner Katri K?ninki Jorma Isola | 2011 | Cancer Letters2011，，2： | 2 |
| 3 | Trastuzumab-DM1 causes- tumour growth inhibition by mitotic catastrophe in trasmzumab-re- sistant breast cancer cells in vivo显示文摘 | Barok M Tanner M Koninki K | 2011 | Breast Cancer Res2011，13，2： | 1 |
| 4 | Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer显示文摘 | Mark Barok Minna Tanner Katri K?ninki Jorma Isola | 2011 | Cancer Letters2011，，2： | 1 |
| 5 | Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor显示文摘 | Barok M Balazs M Nagy P | 2008 | Cancer Lett2008，260，12： | 1 |
| 6 | Fibrocytes in chronic lung disease facts and controversies显示文摘 | Maharaj SS Baroke E Gauldie J | 2012 | Pulm Pharmaeol Ther2012，25，4： | 1 |
| 7 | ErbB-directed im?munotherapy: antibodies in current practice and promising new agents显示文摘 | Friedlander E Barok M SzollosiJ | 2008 | Immunol Lett2008，116，： | 1 |
| 8 | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo显示文摘 | Barok M Tanner M Koninki K | | 0，，： | 1 |
| 9 | New catalytic matedals from amorphous metal alloys显示文摘 | MOLNAR S SMITH G V BAROK M | 1989 | Adv Catal1989，36，： | 1 |
| 10 | Trastuzumab emtansine:mechanisms of action and drug resistance显示文摘 | Barok M Joensuu H Isola J | 2014 | Breast Cancer Res2014，16，： | 1 |
| 11 | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo显示文摘 | Barok M Tanner M Koninki K | | 0，，02： | 1 |
| 12 | Hyaluronan-induced masking of erbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer显示文摘 | Pályi-Krekk Z Barok M Isola J | | 0，，16： | 1 |
| 13 | Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer显示文摘 | Barok M Tanner M Ktininki K | 2011 | Cancer Lett2011，306，2： | 1 |
| 14 | Trastuzumab emtansine:mechanisms of action and drug resistance 显示文摘 | BAROK M JOENSUU H ISOLA J | 2014 | Breast Cancer Res2014，16，2： | 1 |
| 15 | Hyaluronan-induced masking of erbB2 and CD44-enhanced trastuzumab interualisation in trastuzumab resistant breast cancer显示文摘 | Pa1yi-Krekk Z Barok M lsola J | | 0，，： | 1 |
| 16 | Trastuzumab causes antibody dependent cellular eytotoxicity-mediated growth inhibition of submacroseopie JIMT-L breast cancer xenografts despitc intrinsic drug resistanee显示文摘 | Barok M IsolaJ Palyi Krekk Z | 2007 | Mol Caneer Ther2007，6，7： | 1 |
| 17 | Fibrocytes in chronic lung disease--facts and controversies显示文摘 | Maharaj SS Baroke E Gauldie J | 2012 | Pulm Pharmacol Ther2012，25，4： | 1 |
| 18 | Die hard: are cancer stem ceils the Bruce Willises of tumor biology? 显示文摘 | FAbiAn A Barok M Vereb G | 2009 | Cytometry A2009，75，1： | 1 |
| 19 | Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo显示文摘 | BAROK M TANNER M KNINKI K | 2011 | Breast Cancer Res2011，13，2： | 1 |
| 20 | New catalytic materials from amorphous metal alloys 显示文摘 | Molnar S Smith G V Barok M | 1989 | Adv Catal1989，36，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员